Citigroup Issues Positive Forecast for Zymeworks (NASDAQ:ZYME) Stock Price

Key Points

• Citigroup raised its Zymeworks price target from $39 to $44 and maintained a “buy” rating, implying about 50.6% upside from the prior close.
• Analyst sentiment is broadly positive: 12 analysts rate the stock Buy, one Hold and one Sell; the consensus is “Moderate Buy,” with an average target of $42.67.
• Zymeworks reported quarterly EPS of $2.28, narrowly beating the $2.27 consensus, and revenue of $512.92 million versus estimates of $227.40 million. Shares nevertheless fell $2.25 to $29.21 in Wednesday trading.

Zymeworks (NASDAQ:ZYME - Get Free Report) had its target price increased by Citigroup from $39.00 to $44.00 in a report issued on Wednesday, Benzinga reports. The firm currently has a "buy" rating on the stock. Citigroup's price objective indicates a potential upside of 50.63% from the company's previous close.

Several other research analysts also recently weighed in on the stock. HC Wainwright lifted their target price on shares of Zymeworks from $55.00 to $56.00 and gave the stock a "buy" rating in a research report on Tuesday. JPMorgan Chase & Co. upped their price target on shares of Zymeworks from $31.00 to $33.00 and gave the company an "overweight" rating in a research report on Thursday, September 3rd. Truist Financial raised their price objective on shares of Zymeworks from $35.00 to $36.00 and gave the stock a "buy" rating in a research note on Tuesday. Citizens Jmp reiterated a "market outperform" rating and set a $32.00 price objective on shares of Zymeworks in a research report on Wednesday, August 26th. Finally, Deutsche Bank Aktiengesellschaft set a $32.00 target price on shares of Zymeworks in a research note on Wednesday, August 26th. Twelve investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $42.67.

Zymeworks Stock Performance

ZYME traded down $2.25 during trading on Wednesday, reaching $29.21. The company had a trading volume of 338,037 shares, compared to its average volume of 781,592. The firm's 50-day simple moving average is $27.50 and its 200 day simple moving average is $25.42. The company has a market cap of $2.06 billion, a price-to-earnings ratio of 56.44 and a beta of 1.32. Zymeworks has a 12-month low of $18.20 and a 12-month high of $31.97.

Zymeworks (NASDAQ:ZYME - Get Free Report) last posted its quarterly earnings data on Monday, November 9th. The company reported $2.28 EPS for the quarter, beating analysts' consensus estimates of $2.27 by $0.01. Zymeworks had a net margin of 16.10% and a return on equity of 25.07%. The company had revenue of $512.92 million during the quarter, compared to analyst estimates of $227.40 million. During the same period in the prior year, the firm earned ($0.26) earnings per share. The business's quarterly revenue was up 828.7% on a year-over-year basis. On average, sell-side analysts expect that Zymeworks will post 1.32 EPS for the current year.

Insiders Place Their Bets

In other news, EVP Adam Schayowitz sold 13,832 shares of the company's stock in a transaction dated Friday, October 9th. The stock was sold at an average price of $25.85, for a total value of $357,557.20. Following the transaction, the executive vice president owned 23,205 shares in the company, valued at $599,849.25. This represents a 37.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 37.73% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Fisher Asset Management LLC boosted its stake in shares of Zymeworks by 759.9% during the 3rd quarter. Fisher Asset Management LLC now owns 608,612 shares of the company's stock valued at $16,122,000 after buying an additional 537,837 shares during the period. Russell Investments Group Ltd. increased its stake in shares of Zymeworks by 104.7% in the third quarter. Russell Investments Group Ltd. now owns 97,994 shares of the company's stock worth $2,596,000 after acquiring an additional 50,127 shares during the last quarter. Calamos Advisors LLC acquired a new position in shares of Zymeworks in the third quarter worth $1,232,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Zymeworks during the third quarter worth $96,000. Finally, ProShare Advisors LLC raised its holdings in shares of Zymeworks by 91.5% during the third quarter. ProShare Advisors LLC now owns 16,390 shares of the company's stock worth $434,000 after acquiring an additional 7,833 shares in the last quarter. 92.89% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Zymeworks

Investors following ZYME have been watching these headlines:

• Positive Sentiment: Higher 2026 earnings guidance: Zymeworks raised its earnings outlook for the year, supporting the investment case. Zymeworks raises 2026 earnings guidance
• Positive Sentiment: Profitability and revenue beat: The company swung to a profit, with reported third-quarter revenue of $256.5 million versus a FactSet estimate of $227.4 million. A $250 million Jazz milestone was a key contributor, though its size suggests the quarter’s results may not reflect recurring revenue. Zymeworks swings to a profit on a Jazz milestone
• Neutral Sentiment: EPS estimates were mixed: Zymeworks reported $2.28 per share—slightly above one consensus estimate of $2.27, but below Zacks’ $2.40 estimate. This leaves the earnings-per-share read less uniformly positive than the revenue result. Zacks earnings report

Zymeworks Company Profile

Zymeworks Inc. is a biotechnology company headquartered in Vancouver, Canada, that develops engineered medicines, with a focus on treatments for cancer and other serious diseases. Its antibody-engineering technologies are designed to create therapies that can engage multiple biological targets or modify immune responses. The company's lead program is zanidatamab, a HER2-targeted bispecific antibody. In the United States, it is marketed by partner Jazz Pharmaceuticals as Ziihera for certain adults with previously treated, unresectable or metastatic biliary tract cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.